SCHEMBL16356142

SCHEMBL16356142

Cc1ccc([C@H](C)N2C(=O)c3ccccc3C2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
TDP1 Q9NUW8 2/20 0.47
POLB P06746 2/20 0.46
ELANE P08246 1/20 0.42
CASP3 P42574 1/20 0.42
RPS6KA2 Q15349 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
HKDC1 Q2TB90 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GRM4 Q14833 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10926240 1.00 ALDH1A1 (0.51) ALDH1A1LMNAHTTTDP1POLB
SCHEMBL607042 0.88 LMNA (0.58) ALDH1A1LMNATDP1POLBCASP3
SCHEMBL6925572 0.88 LMNA (0.58) ALDH1A1LMNATDP1POLBCASP3
SCHEMBL29393294 0.88 LMNA (0.58) ALDH1A1LMNATDP1POLBCASP3
SCHEMBL13878069 0.87 ALDH1A1 (0.41) ALDH1A1LMNAHTTPOLB
SCHEMBL12184795 0.85 LMNA (0.47) ALDH1A1LMNAHTTTDP1POLB
SCHEMBL31706143 0.85 LMNA (0.47) ALDH1A1LMNAHTTTDP1POLB
SCHEMBL16321480 0.85 LMNA (0.51) ALDH1A1LMNAHTTTDP1POLB
SCHEMBL2002904 0.85 LMNA (0.47) ALDH1A1LMNAHTTTDP1POLB
SCHEMBL12845880 0.85 KMT2A (0.55) LMNATDP1CASP3MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 US disclosed
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2016-02-04 US disclosed
US-9181200-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2015-11-10 US disclosed
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD ALDH1A1 1556/4885LMNA 401/4885HTT 286/4885
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD ALDH1A1 1556/4885LMNA 401/4885HTT 286/4885
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD ALDH1A1 1556/4885LMNA 401/4885HTT 286/4885
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD ALDH1A1 1556/4885LMNA 401/4885HTT 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.